Anthracycline-induced cardiotoxicity. A case presentation

Authors

  • Mayelin Baró Rojas
  • Edmundo Luis Sánchez González
  • Wilfredo García Sotolongo

Abstract

A case attended in the “Dr. Antonio Luaces Iraola” Provincial Hospital of Ciego de Avila is presented,
that it considers important for its little frequency. A 54-year-old woman with injury in the palate, of big
size, rounded, of hard and irregular surface, to which some studies are carried out and it diagnosed to
her a quite differentiated Non-Hodgkin Lymphoma. It offers chemotherapy treatment of 8 cycles every
21 days, to 7th cycle with an accumulate dose of doxorubicin 660mg/m2, begins with dyspnea to the
big efforts, its clinical condition was worsening and she arrives to the Hospital with an acute pulmonary
edema, clinical studies were carried out. The case is concluded with dilated cardiomyopathy
diagnosis.

Downloads

Download data is not yet available.

Author Biographies

Mayelin Baró Rojas

Especialista de 1er Grado en Cardiología. Máster en Urgencias Médicas. Profesor Instructor.

Edmundo Luis Sánchez González

Especialista de 2do Grado en Cardiología. Máster en Urgencias Médicas. Profesor Asistente.

Wilfredo García Sotolongo

Licenciado en Enfermería. Máster Urgencias Médicas. Profesor Instructor.

References

Braunwald E. Braunwald Heart Disease. 7 ed. New York: Saunders; 2005.

Lipshutz S. Late cardiac efects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Eng J Med. 2003; 324:808-15.

Kesevan S. Anthracycline-induced cardiotoxicity. Ann Intern Med. 2006; 125:47-58.

Von Hoff D. Daunomycin-induced cardiotoxity in children and adults. Am J Med. 1997; 62:200-8.

Arsen Rl. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 2006; 70:73-77.

Steinherz L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Ass. 2008; 266:1672-7.

Geiger S, Lange V. Suhl P, Heinemam V, Stembler HJ. Anticancer therapy induced cardiotoxicity review of the literature. Anticancer Drugs. 2010: 21(6): 578-90.

Shan K, Lincoff AM. Young JB. Antrathracycline induced cardiotoxicity. Ann Inter Med. 1996; 125(1): 47-58.

Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol [Internet]. 1991 [citado 23 Ene 2013]. 9(7): 1215-1223. Disponible en: http://jco.ascopubs.org/content/9/7/1215.short

Nieto Y, Cagnoni A. Cardiac toxicity following high dose ciclophosphamide, cisptatin, and BNC (stamp-I) for breast cancer. Biol Blood Marrow Transpl. 2012; 6(2A): 198-2003.

Kerkela R, Gazette l. Cardiotoxicity of the cancer therapheutic agent imatinibmesylate. Nat Med. 2006; 12(8): 908-16.

Rosti G, Martinelli G. Cardiotoxiciti of the chemotherapeutic agents: incidence treatment and prevention. Drug Safety. 2011; 22:302.

Stemmber HJ. Anticancer therapy induced cardiotoxicity review of the literature. Anticancer Drugs. 2010; 21(6): 578-90.

Published

2013-12-19

How to Cite

1.
Baró Rojas M, Sánchez González EL, García Sotolongo W. Anthracycline-induced cardiotoxicity. A case presentation. Mediciego [Internet]. 2013 Dec. 19 [cited 2024 Dec. 11];19(2). Available from: https://revmediciego.sld.cu/index.php/mediciego/article/view/278

Issue

Section

Case Report

Most read articles by the same author(s)